Bone and Mineral Metabolism Disorders News

A study of patients receiving hemodialysis in Japan demonstrated the efficacy of tenapanor for treating hyperphosphatemia with fewer daily pills required in a 26-week period.

Investigators found a “relatively high” prevalence of pre-dialysis hyperkalemia among patients on hemodialysis, with women, younger patients and Hispanic individuals showing higher rates of the condition, according to findings.

For patients with advanced chronic kidney disease, the prevalence of frailty varied widely based on the tool used for assessment, according to a study conducted in Canada.

Patients aged 75 years and older with chronic kidney disease, type 2 diabetes, hypertension and hyperkalemia had “significant reductions in serum potassium” after treatment with patiromer, according to results of a secondary analysis.

Defining hypothyroidism by thyroid-stimulating hormone level, researchers found the condition was more common in patients with worsening levels of kidney function (as determined by eGFR slope), as well as in those who had proteinuria.

For patients with advanced chronic kidney disease, low serum zinc concentration was linked to an increased likelihood of hospitalizations due to infections. This elevated risk was especially high for individuals on proton pump inhibitors.

Compared with standard targets, lower serum phosphate levels led to smaller changes in coronary artery calcification scores, suggesting stricter phosphate control may delay calcification progression for patients on hemodialysis.

Adding to data from clinical trials demonstrating the efficacy of sucroferric oxyhydroxide in phosphate management for patients on hemodialysis, researchers from Spain have identified several benefits of the drug in “real-world” settings.

Patients categorized as frail and who were undergoing evaluation for kidney transplantation were “more likely” to have care partners who were also frail, according to a study.

An analysis of participants enrolled in the Chronic Renal Insufficiency Cohort study showed those with low or high serum magnesium levels had greater mortality rates.